Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight management | Not covered |
BCBSIL and its pharmacy benefit manager, Prime Therapeutics, offer weight-loss and GLP-1 coverage as an optional benefit that each employer group chooses to add or leave out, so many plans exclude anti-obesity drugs entirely. Where an employer elected the benefit, Wegovy is covered with prior authorization, generally at a BMI of 30 or higher (or 27 or higher with a weight-related condition) plus documented diet and lifestyle efforts. Members should confirm with their plan or employer whether weight-loss drugs are included before assuming coverage.
Source: Pharmacy Benefit for GLP-1 and/or Anti-Obesity Drug Therapy. Verified August 28, 2026.
Plan type: Commercial non-Medicare.
What it costs once they say yes. With commercial insurance the manufacturer savings card takes Wegovy to as little as $25 a month. Your plan sets the copay before the card applies. What Wegovy costs with your plan.
This varies by plan. BCBSIL runs weight-loss and GLP-1 coverage through Prime Therapeutics as optional employer-group programs (GLP-1 New to Therapy, GLP-1 30-Day Max, and Anti-Obesity 30-Day Max). BCBSIL states the categories and medications included may vary according to employer group selections, so Wegovy is covered only when the employer purchased anti-obesity or GLP-1 drug coverage. Plans that did not elect it treat weight-loss drugs as a benefit exclusion, not a medical-necessity denial.
If the weight-loss exclusion above applies to you, you are paying for this yourself.
Coverage by indication
| BMI threshold | 30, or 27 with a weight-related comorbidity |
| Step therapy | Varies by plan; some plans require documentation of prior anti-obesity medications |
What the prior authorization needs:
- Coverage applies only if the employer group elected the GLP-1 or anti-obesity drug benefit through Prime Therapeutics; many plans exclude weight-loss drugs entirely.
- Prior authorization applies where the benefit is elected, administered under BCBSIL's weight management program with Prime Therapeutics.
- BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, per standard weight-management criteria. BCBSIL does not publish its exact clinical criteria document.
- Documentation of a reduced-calorie diet and increased physical activity, or participation in a lifestyle or behavioral weight-management program.
- Reauthorization typically requires at least 5% weight loss from baseline.
Source: Pharmacy Benefit for GLP-1 and/or Anti-Obesity Drug Therapy. payer provider bulletin. Verified August 28, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
Ozempic, Mounjaro and Rybelsus on BCBS Illinois plans
Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes, not weight loss.
Does BCBS Illinois cover Ozempic?
Yes, with prior approval. BCBS Illinois pays for Ozempic once your prescriber gets the plan to sign off.
Blue Cross and Blue Shield of Illinois covers Ozempic for type 2 diabetes on its 2026 commercial drug lists, where it sits as a preferred brand and requires prior authorization plus a quantity limit of one pen every 28 days. Approval requires a documented diagnosis of type 2 diabetes and runs for 12 months before it has to be renewed. BCBSIL does not cover Ozempic for weight loss, because Ozempic is FDA-approved only for type 2 diabetes. The weight-loss semaglutide is Wegovy, a separate higher-dose product with its own coverage rules.
Verified August 27, 2026.
What BCBS Illinois requires for Ozempic
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes
- Prior authorization approved before the pharmacy fills it
- Quantity limit of one pen per 28 days
- Ozempic is a preferred-brand agent, so no step through another GLP-1 is required
- Approval lasts 12 months, then must be renewed
- Type 2 diabetes diagnosis and 12-month approval terms come from the Prime Therapeutics GLP-1 agonist prior authorization criteria (effective 04-01-2026): https://web.primetherapeutics.com/provider/external/commercial/common/doc/en-us/Accord_Clinical_Criteria_Choice_Glucagon-Like_Peptide-1_GLP-1_Agonists.pdf
Source: BCBSIL 2656-Y IL Balanced Drug List, July 2026 (HCSC, Prime Therapeutics). Ozempic listed as preferred brand (P) with PA and QL of 1 pen per 28 days.. formulary. Verified August 27, 2026.
Does BCBS Illinois cover Mounjaro?
Yes, with prior approval. BCBS Illinois pays for Mounjaro once your prescriber gets the plan to sign off.
Blue Cross and Blue Shield of Illinois covers Mounjaro (tirzepatide) for type 2 diabetes on its 2026 commercial drug list, with prior authorization and quantity limits. The prior authorization criteria require that the patient has already tried an antidiabetic agent, so a first-line drug like metformin usually comes first. BCBSIL will not cover Mounjaro for weight loss. Tirzepatide for weight management is sold as Zepbound, which BCBSIL lists separately and covers only when the employer group elects an anti-obesity benefit.
Verified August 27, 2026.
What BCBS Illinois requires for Mounjaro
| Step therapy |
What the prior authorization needs:
- Prior authorization required. The GLP-1 agonists program covers Mounjaro when it is used per FDA-approved labeling and dosing.
- Step therapy applies. Approval requires a prior trial of an antidiabetic agent, typically metformin, before Mounjaro.
- Quantity limit of 4 pens per 28 days for the 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg strengths, and 4 pens per 180 days for the 2.5 mg starter strength, per the July 2026 Multi-Tier Basic Annual Drug List (https://www.bcbsil.com/il/documents/rx-drugs/drug-lists/multi-basic-annual-il-2026.pdf).
- Listed as a covered brand on the July 2026 drug list. The exact payment tier depends on the member benefit design, since this list does not print a per-drug tier and excludes non-preferred drugs.
- Not covered for weight loss. Zepbound is the tirzepatide product for weight management and is listed separately, subject to its own prior authorization and an employer-elected anti-obesity benefit.
Policy 23466.0726. Source: BCBSIL Prior Authorization/Step Therapy Program, GLP-1 Agonists, July 2026. pa_policy. Verified August 27, 2026.
Does BCBS Illinois cover Rybelsus?
Yes, with prior approval. BCBS Illinois pays for Rybelsus once your prescriber gets the plan to sign off.
Blue Cross and Blue Shield of Illinois covers Rybelsus for type 2 diabetes, with prior authorization required through its pharmacy benefit manager, Prime Therapeutics. Approval needs a documented type 2 diabetes diagnosis and a prior trial of another antidiabetic agent, and quantity limits apply. Rybelsus is not covered for weight loss, because it is FDA-approved for type 2 diabetes only. The weight-loss semaglutide is Wegovy, which BCBS Illinois lists separately with its own prior authorization.
Verified August 28, 2026.
What BCBS Illinois requires for Rybelsus
| Step therapy |
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes
- Prior trial of another antidiabetic agent, per the BCBS Illinois GLP-1 agonist criteria
- Quantity limits apply per the July 2026 Multi-Tier Basic Annual Drug List (form 2656-1N IL): 30 tablets per 30 days for the 7 mg and 14 mg doses, and 30 tablets per 180 days for the 3 mg starting dose
Policy 23466.0726. Source: BCBSIL Prior Authorization/Step Therapy Program, GLP-1 (glucagon-like peptide-1) Agonists clinical criteria 23466.0726. payer prior-authorization policy. Verified August 28, 2026.
Recent change: As of the July 2026 formulary, Rybelsus is listed and covered for type 2 diabetes with prior authorization.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time.
What it costs without insurance
The programs below bill you directly.
Frequently asked questions
Does BCBS Illinois cover Wegovy?
Yes on some plans. BCBSIL and its pharmacy benefit manager, Prime Therapeutics, offer weight-loss and GLP-1 coverage as an optional benefit that each employer group chooses to add or leave out, so many plans exclude anti-obesity drugs entirely. Where an employer elected the benefit, Wegovy is covered with prior authorization, generally at a BMI of 30 or higher (or 27 or higher with a weight-related condition) plus documented diet and lifestyle efforts. Members should confirm with their plan or employer whether weight-loss drugs are included before assuming coverage. This reflects the published policy verified August 2026.
Why might BCBS Illinois deny Wegovy even if I meet the criteria?
BCBSIL runs weight-loss and GLP-1 coverage through Prime Therapeutics as optional employer-group programs (GLP-1 New to Therapy, GLP-1 30-Day Max, and Anti-Obesity 30-Day Max). BCBSIL states the categories and medications included may vary according to employer group selections, so Wegovy is covered only when the employer purchased anti-obesity or GLP-1 drug coverage. Plans that did not elect it treat weight-loss drugs as a benefit exclusion, not a medical-necessity denial.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
